Nicotine
Yes
No
Medical Assistance Fund
Active ingredient: Nicotine
General information
Subsidy Information and Financing Scheme
[MAF] Nicotine [Nicotinell] Transdermal Patch 7 mg/24 hours, 14 mg/24 hours, and 21 mg/24 hours
As an aid for smoking cessation in patients who are willing to quit and enrolled in a smoking cessation counselling program, with a documented Fagerstrom score of three and above. The smoking cessation counselling programme should include a minimum of three counselling sessions, and counselling should be delivered by a healthcare professional trained in smoking cessation counselling, at an approved setting. Nicotine replacement therapies should not be used in combination with varenicline for smoking cessation.
[MAF] Nicotine [Nicotinell] Lozenge 1 mg
As an aid for smoking cessation in patients who are willing to quit and enrolled in a smoking cessation counselling program, with a documented Fagerstrom score of three and above. The smoking cessation counselling programme should include a minimum of three counselling sessions, and counselling should be delivered by a healthcare professional trained in smoking cessation counselling, at an approved setting. Nicotine replacement therapies should not be used in combination with varenicline for smoking cessation.
[MAF] Nicotine [Nicorette] Chewing Gum 2 mg, 4 mg
As an aid for smoking cessation in patients who are willing to quit and enrolled in a smoking cessation counselling program, with a documented Fagerstrom score of three and above. The smoking cessation counselling programme should include a minimum of three counselling sessions, and counselling should be delivered by a healthcare professional trained in smoking cessation counselling, at an approved setting. Nicotine replacement therapies should not be used in combination with varenicline for smoking cessation.
Drug Guidance for Subsidy
19/12/2022 Nicotine replacement therapies to aid smoking cessation
The Ministry of Health’s Drug Advisory Committee has recommended:
Nicotine 7 mg/ 24 hours, 14 mg/ 24 hours, and 21 mg/ 24 hours transdermal patches (Nicotinell);
Nicotine 2 mg and 4 mg chewing gums (Nicorette); and
Nicotine 1 mg lozenge (Nicotinell)
to be used as an aid for smoking cessation in patients who are willing to quit and enrolled in a smoking cessation counselling program, with a documented Fagerstrom score of three and above. The smoking cessation counselling programme should include a minimum of three counselling sessions, and counselling should be delivered by a healthcare professional trained in smoking cessation counselling, at an approved setting. Nicotine replacement therapies should not be used in combination with varenicline for smoking cessation.
Funding status
[R] Nicotine 7 mg/ 24 hours, 14 mg/ 24 hours, 21 mg/ 24 hours transdermal patches (Nicotinell), nicotine 2 mg and 4 mg chewing gums (Nicorette) and nicotine 1 mg lozenge (Nicotinell) are recommended for inclusion on the MOH Medication Assistance Fund (MAF) for the abovementioned indication from 1 February 2023.
[NR] MAF assistance does not apply to any strengths of nicotine transdermal patch (Nicorette) and nicotine chewing gum (Nicotinell).
General Availability in Public Healthcare Institution
Note:
General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.
Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration
Availability information
Formulation | Public Healthcare Institution |
|---|---|
Nicorette Chewing Gum 2 mg |
|
Nicorette Chewing Gum 4 mg |
|
Nicotinell Lozenge 1 mg |
|
Nicotinell Transdermal Patch 7 mg/24 hours |
|
Nicotinell Transdermal Patch 14 mg/24 hours |
|
Nicotinell Transdermal Patch 21 mg/24 hours |
|
Patch, Extended Release 10 mg/16 hours |
|
Patch, Extended Release 15 mg/16 hours |
|
Patch, Extended Release 25 mg/16 hours |
|
Gum, Chewing 2 mg |
|
Gum, Chewing 4 mg |
|
Registered Product(s) Information
Clinical and product info
Clinical info | Product Info |
|---|---|
Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch. The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice. | Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch for the most updated product information. |
Oral
* Clinical information is available for this product.
Transdermal
NICORETTE INVISI TRANSDERMAL PATCH 10MG/16 HOURS [SIN14294P]*
NICORETTE INVISI TRANSDERMAL PATCH 15MG/16 HOURS [SIN14295P]*
NICORETTE INVISI TRANSDERMAL PATCH 25MG/16 HOURS [SIN14296P]*
NICOTINELL TTS 10 TRANSDERMAL THERAPEUTIC SYSTEM 7 MG/24 HRS [SIN06528P]*
NICOTINELL TTS 20 TRANSDERMAL THERAPEUTIC SYSTEM 14 MG/24 HRS [SIN06527P]*
NICOTINELL TTS 30 TRANSDERMAL THERAPEUTIC SYSTEM 21 MG/24 HRS [SIN06529P]*
* Clinical information is available for this product.
